All In Biotech

Drug Trial Radar · NCT04411641

Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)

A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Jul 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,131 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,131

Actual

Start

Sep 24, 2020

Primary completion

Aug 29, 2024

Study completion Aug 29, 2024

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Jun 2, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in NRSPMS Secondary Objective: To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic resonance imaging (MRI) lesions, cognitive performance, physical function, and quality of life To evaluate safety and tolerability of SAR442168 To evaluate population pharmacokinetics (PK) of SAR442168 and relevant metabolites in NRSPMS and its relationship to efficacy and safety To evaluate pharmacodynamics (PD) of SAR442168

Conditions

  • Non-relapsing Secondary Progressive Multiple Sclerosis

Interventions

  • TolebrutinibDrug

    Pharmaceutical form: Film-coated tablet Route of administration: Oral

  • Placebo to match TolebrutinibDrug

    Pharmaceutical form: Film-coated tablet Route of administration: Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Onset of 6-Month Confirmed Disability Progression (CDP) as Assessed by Expanded Disability Status Scale (EDSS)Time frame: Baseline (Day 1) up to approximately 47 months

Locations

306 sites in 31 countries. Site status is shown where the registry gives one.

  • University of Alabama MS Center-Site Number:8400013

    Birmingham, Alabama

  • Center for Neurology and Spine-Site Number:8400089

    Phoenix, Arizona

  • Arcadia Neurology Center-Site Number:8400070

    Arcadia, California

  • UC San Diego ACTRI-Site Number:8400101

    La Jolla, California

  • Collaborative Neuroscience Research-Site Number:8400045

    Long Beach, California

  • Multiple Sclerosis Center-Site Number:8400143

    Los Angeles, California

  • University of San Francisco, Sandler Neurosciences Center-Site Number:8400137

    San Francisco, California

  • Harbor UCLA-Site Number:8400088

    Torrance, California

  • Regina Berkovich, MD, PhD-Site Number:8400059

    West Hollywood, California

  • Mountain Neurological Research Center, Inc.-Site Number:8400128

    Basalt, Colorado

  • University of Colorado-Site Number:8400012

    Denver, Colorado

  • Advanced Neurosciences Research-Site Number:8400025

    Fort Collins, Colorado

  • South Florida Neurology Associates-Site Number:8400029

    Boca Raton, Florida

  • Neurology Associates, PA-Site Number:8400004

    Maitland, Florida

  • Aqualane Clinical Research-Site Number:8400027

    Naples, Florida

  • Axiom Clinical Research of Florida-Site Number:8400001

    Tampa, Florida

  • University of South Florida-Site Number:8400006

    Tampa, Florida

  • Meridian Clinical Research-Site Number:8400003

    Savannah, Georgia

  • Consultants In Neurology-Site Number:8400011

    Northbrook, Illinois

  • University of Kansas Medical Center-Site Number:8400023

    Kansas City, Kansas

  • CHI Saint Joseph Medical Group Neurology-Site Number:8400110

    Lexington, Kentucky

  • Tufts Medical Center-Site Number:8400072

    Boston, Massachusetts

  • University of Massachusetts-Site Number:8400014

    Worcester, Massachusetts

  • Wayne State University-Site Number:8400046

    Detroit, Michigan

  • The Memorial Hospital-Site Number:8400033

    Owosso, Michigan

  • Minneapolis Clinic of Neurology-Site Number:8400051

    Minneapolis, Minnesota

  • Mayo Clinic-Site Number:8400111

    Rochester, Minnesota

  • Missouri Baptist Medical Center-Site Number:8400019

    St Louis, Missouri

  • Lou Ruvo Center for Brain Health-Site Number:8400117

    Las Vegas, Nevada

  • Holy Name Hospital-Site Number:8400104

    Teaneck, New Jersey

  • University of New Mexico-Site Number:8400032

    Albuquerque, New Mexico

  • Icahn School of Medicine at Mount Sinai (Department of Endoc-Site Number:8400038

    New York, New York

  • Neurology Associates of Stony Brook-Site Number:8400042

    Stony Brook, New York

  • Meridian Clinical Research, LLC-Site Number:8400005

    Raleigh, North Carolina

  • Sanford Brain & Spine Center-Site Number:8400126

    Fargo, North Dakota

  • University Hospitals CMC-Site Number:8400083

    Cleveland, Ohio

  • Cleveland Clinic-Site Number:8400125

    Cleveland, Ohio

  • Optimed Research, LTD-Site Number:8400147

    Columbus, Ohio

  • Neurology Specialists-Site Number:8400002

    Dayton, Ohio

  • Columbus Neuroscience-Site Number:8400010

    Westerville, Ohio

Showing 40 of 306 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.